18.44
1.14 (6.59%)
| Previous Close | 17.30 |
| Open | 17.62 |
| Volume | 1,654,769 |
| Avg. Volume (3M) | 983,079 |
| Market Cap | 932,073,664 |
| Price / Earnings (Forward) | 19.72 |
| Price / Sales | 583.74 |
| Price / Book | 48.09 |
| 52 Weeks Range | |
| Earnings Date | 24 Mar 2026 |
| Diluted EPS (TTM) | -3.69 |
| Total Debt/Equity (MRQ) | 3.98% |
| Current Ratio (MRQ) | 10.44 |
| Operating Cash Flow (TTM) | -127.65 M |
| Levered Free Cash Flow (TTM) | -72.82 M |
| Return on Assets (TTM) | -58.15% |
| Return on Equity (TTM) | -150.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | KalVista Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.63 |
|
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.47% |
| % Held by Institutions | 112.39% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Vr Adviser, Llc | 31 Dec 2025 | 6,728,985 |
| Frazier Life Sciences Management, L.P. | 31 Dec 2025 | 5,039,867 |
| Point72 Asset Management, L.P. | 31 Dec 2025 | 2,283,766 |
| Woodline Partners Lp | 31 Dec 2025 | 1,921,092 |
| Vestal Point Capital, Lp | 31 Dec 2025 | 1,890,000 |
| Kynam Capital Management, Lp | 31 Dec 2025 | 1,810,954 |
| Parkman Healthcare Partners Llc | 31 Dec 2025 | 1,768,508 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 37.00 (HC Wainwright & Co., 100.65%) | Buy |
| Median | 36.00 (95.23%) | |
| Low | 35.00 (Needham, 89.81%) | Buy |
| Average | 36.00 (95.23%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 16.80 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 09 Jan 2026 | 37.00 (100.65%) | Buy | 16.80 |
| Needham | 09 Jan 2026 | 35.00 (89.80%) | Buy | 16.80 |
| 06 Jan 2026 | 32.00 (73.54%) | Buy | 15.75 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Feb 2026 | Announcement | KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 08 Jan 2026 | Announcement | KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results |
| 22 Dec 2025 | Announcement | KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |